<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425801</url>
  </required_header>
  <id_info>
    <org_study_id>M/100977/202</org_study_id>
    <nct_id>NCT01425801</nct_id>
  </id_info>
  <brief_title>Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.</brief_title>
  <official_title>A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Doses of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Persistent Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacodynamics of single doses of inhaled
      LAS100977 QD in patients with persistent asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2011</start_date>
  <completion_date type="Actual">February 1, 2012</completion_date>
  <primary_completion_date type="Actual">February 1, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>+15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose</time_frame>
    <description>The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>+15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose</time_frame>
    <description>The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Trough Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Baseline and +23 h and +24 h post-dose</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-24h at Day 1</measure>
    <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h and +24 h</time_frame>
    <description>FEV1 was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values of Forced Expiratory Volume (FEV1) at Each Timepoint</measure>
    <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint</measure>
    <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint</measure>
    <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Peak Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Forced Vital Capacity (FVC)</measure>
    <time_frame>+15 min, +30 min, +1 h, +2 h, +3 h, +4 h</time_frame>
    <description>The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Forced Vital Capacity (FVC)</measure>
    <time_frame>+15 min, +30 min, +1 h, +2 h, +3 h, +4 h</time_frame>
    <description>The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Trough Forced Vital Capacity (FVC)</measure>
    <time_frame>Baseline and +23 h +24 h post-dose</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Normalized Forced Vital Capacity (FVC) Area Under the Curve (AUC)</measure>
    <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h and +24 h</time_frame>
    <description>FVC was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values of Forced Vital Capacity (FVC) at Each Timepoint</measure>
    <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity (FVC) at Each Timepoint</measure>
    <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h</time_frame>
    <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>LAS100977 0.625 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose LAS100977 0.625 μg, during double-blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS100977 1.25 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose LAS100977 1.25 μg, during double-blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS100977 2.5 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose LAS100977 2.5 μg, during double-blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salbutamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single-dose salbutamol 400 μg, during double-blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to LAS100977, and placebo to salbutamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS100977 0.313 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose LAS100977 0.313 μg, during double-blind treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS100977 0.313 μg</intervention_name>
    <description>Dry powder inhalation, once-daily, single-dose</description>
    <arm_group_label>LAS100977 0.313 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS100977 0.625 μg</intervention_name>
    <description>Dry powder inhalation, once-daily, single-dose</description>
    <arm_group_label>LAS100977 0.625 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS100977 1.25 μg</intervention_name>
    <description>Dry powder inhalation, once-daily, single-dose</description>
    <arm_group_label>LAS100977 1.25 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS100977 2.5 μg</intervention_name>
    <description>Dry powder inhalation, once-daily, single-dose</description>
    <arm_group_label>LAS100977 2.5 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol 400 μg</intervention_name>
    <description>Pressurized inhalation suspension, once-daily, single-dose</description>
    <arm_group_label>Salbutamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol placebo</intervention_name>
    <description>Pressurized inhalation, once-daily</description>
    <arm_group_label>LAS100977 0.625 μg</arm_group_label>
    <arm_group_label>LAS100977 1.25 μg</arm_group_label>
    <arm_group_label>LAS100977 2.5 μg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>LAS100977 0.313 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS100977 placebo</intervention_name>
    <description>Dry powder inhalation, once-daily</description>
    <arm_group_label>Salbutamol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male and female patients aged 18-70 years (both included).

          2. Clinical diagnosis of persistent asthma (according to GINA guidelines 2009 update) for
             at least 6 months prior to screening.

          3. Screening FEV1 value of 60% &lt; FEV1 ≤ 85% of the predicted normal value.

          4. FEV1 reversibility ≥ 12% and an absolute increase of at least 200 ml over baseline
             value after inhalation of 400µg (four inhalations) of salbutamol.

          5. Pre-dose FEV1 value of first treatment period within the range of ± 20% of the FEV1
             measured at screening prior to salbutamol inhalation.

          6. Patients on a stable dose and regimen

        Exclusion Criteria:

          1. Current smokers, former smokers within the last 6 months, or ex-smokers with a history
             of more than 10 pack-years.

          2. Patients diagnosed with COPD.

          3. Recent Respiratory tract infections within 6 weeks before Screening Visit.

          4. Intubation (ever) or hospitalization for longer than 24 hours for the management of an
             asthma exacerbation within the preceding 6 weeks of the screening visit.

          5. Clinically significant respiratory conditions.

          6. Clinically significant cardiovascular conditions.

          7. Patients unable to properly use a dry powder or pMDI inhaler device or unable to
             perform acceptable spirometry.

          8. Clinically relevant abnormalities laboratory, ECG parameters or physical examination
             results at the screening evaluation that in the investigator's opinion, preclude study
             participation.

          9. Patients who intend to use any concomitant medication not permitted by this protocol
             or who have not undergone the required washout period for a particular prohibited
             medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Astbury, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Almirall Investigational Sites#6</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#4</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Berlin</city>
        <zip>14057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#3</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#2</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#8</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#5</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#2</name>
      <address>
        <city>London</city>
        <zip>W1G 8HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almirall Investigational Sites#1</name>
      <address>
        <city>Manchester</city>
        <zip>M3 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3968&amp;filename=Synopsis-M-100977-202-Final.pdf</url>
    <description>Synopsis-M-100977-202</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2011</study_first_posted>
  <results_first_submitted>February 27, 2017</results_first_submitted>
  <results_first_submitted_qc>June 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 26, 2018</results_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in 10 sites in Germany and United Kingdom, 9 of which randomized patients</recruitment_details>
      <pre_assignment_details>Screening took place 12-16 days before randomization. After screening, eligible patients entered a run-in period to assess clinical stability. A total of 115 patients were screened; 62 patients were assessed as eligible and randomized; 53 were not randomized due to screening failure (primarily non-fulfillment of inclusion/exclusion criteria)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence A</title>
          <description>Salbutamol 400 μg - LAS100977 0.313 μg - Placebo - LAS100977 0.625 μg - LAS100977 2.5 μg - LAS100977 1.25 μg</description>
        </group>
        <group group_id="P2">
          <title>Sequence B</title>
          <description>LAS100977 0.313 μg - LAS100977 0.625 μg - Salbutamol 400 μg - LAS100977 1.25 μg - Placebo - LAS100977 2.5 μg</description>
        </group>
        <group group_id="P3">
          <title>Sequence C</title>
          <description>LAS100977 0.625 μg - LAS100977 1.25 μg - LAS100977 0.313 μg - LAS100977 2.5 μg - Salbutamol 400 μg - Placebo</description>
        </group>
        <group group_id="P4">
          <title>Sequence D</title>
          <description>LAS100977 1.25 μg - LAS100977 2.5 μg - LAS100977 0.625 μg - Placebo - LAS100977 0.313 μg - Salbutamol 400 μg</description>
        </group>
        <group group_id="P5">
          <title>Sequence E</title>
          <description>LAS100977 2.5 μg - Placebo - LAS100977 1.25 μg - Salbutamol 400 μg - LAS100977 0.625 μg - LAS100977 0.313 μg</description>
        </group>
        <group group_id="P6">
          <title>Sequence F</title>
          <description>Placebo - Salbutamol 400 μg - LAS100977 2.5 μg - LAS100977 0.313 μg - LAS100977 1.25 μg - LAS100977 0.625 μg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Stability criteria not fullfilled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not able to maintain visit schedule</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Population</title>
          <description>Safety population defined as all patients who were randomized and received at least one dose of investigational medicinal product</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.</description>
        <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.202" spread="0.045"/>
                    <measurement group_id="O2" value="0.477" spread="0.045"/>
                    <measurement group_id="O3" value="0.524" spread="0.045"/>
                    <measurement group_id="O4" value="0.573" spread="0.045"/>
                    <measurement group_id="O5" value="0.608" spread="0.045"/>
                    <measurement group_id="O6" value="0.555" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Sequence, treatment and period as fixed effect factors, patient within sequence as random effect and baseline peak FEV1 at each period as a covariate</method_desc>
            <param_type>Least Squares Mean DIfference</param_type>
            <param_value>0.405</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.353</ci_lower_limit>
            <ci_upper_limit>0.458</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Sequence, treatment and period as fixed effect factors, patient within sequence as random effect and baseline peak FEV1 at each period as a covariate</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.371</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.318</ci_lower_limit>
            <ci_upper_limit>0.424</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Sequence, treatment and period as fixed effect factors, patient within sequence as random effect and baseline peak FEV1 at each period as a covariate</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.322</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.269</ci_lower_limit>
            <ci_upper_limit>0.375</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Sequence, treatment and period as fixed effect factors, patient within sequence as random effect and baseline peak FEV1 at each period as a covariate</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.274</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.221</ci_lower_limit>
            <ci_upper_limit>0.327</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.</description>
        <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.555" spread="1.655"/>
                    <measurement group_id="O2" value="18.282" spread="1.651"/>
                    <measurement group_id="O3" value="20.212" spread="1.651"/>
                    <measurement group_id="O4" value="21.809" spread="1.651"/>
                    <measurement group_id="O5" value="23.077" spread="1.650"/>
                    <measurement group_id="O6" value="21.374" spread="1.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Forced Expiratory Volume in One Second (FEV1)</title>
        <description>The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.</description>
        <time_frame>+15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Forced Expiratory Volume in One Second (FEV1)</title>
          <description>The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.855" spread="0.045"/>
                    <measurement group_id="O2" value="3.129" spread="0.045"/>
                    <measurement group_id="O3" value="3.177" spread="0.045"/>
                    <measurement group_id="O4" value="3.225" spread="0.045"/>
                    <measurement group_id="O5" value="3.260" spread="0.045"/>
                    <measurement group_id="O6" value="3.207" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Forced Expiratory Volume in One Second (FEV1)</title>
        <description>The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.</description>
        <time_frame>+15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Forced Expiratory Volume in One Second (FEV1)</title>
          <description>The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.3"/>
                    <measurement group_id="O2" value="2.6" spread="1.3"/>
                    <measurement group_id="O3" value="3.0" spread="1.1"/>
                    <measurement group_id="O4" value="3.1" spread="0.9"/>
                    <measurement group_id="O5" value="3.0" spread="1.1"/>
                    <measurement group_id="O6" value="1.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Trough Forced Expiratory Volume in One Second (FEV1)</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
        <time_frame>Baseline and +23 h and +24 h post-dose</time_frame>
        <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Trough Forced Expiratory Volume in One Second (FEV1)</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
          <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.054" spread="0.039"/>
                    <measurement group_id="O2" value="0.166" spread="0.039"/>
                    <measurement group_id="O3" value="0.205" spread="0.039"/>
                    <measurement group_id="O4" value="0.278" spread="0.039"/>
                    <measurement group_id="O5" value="0.346" spread="0.039"/>
                    <measurement group_id="O6" value="-0.076" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-24h at Day 1</title>
        <description>FEV1 was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
        <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h and +24 h</time_frame>
        <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-24h at Day 1</title>
          <description>FEV1 was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
          <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="59"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.039"/>
                    <measurement group_id="O2" value="0.282" spread="0.039"/>
                    <measurement group_id="O3" value="0.321" spread="0.038"/>
                    <measurement group_id="O4" value="0.390" spread="0.038"/>
                    <measurement group_id="O5" value="0.446" spread="0.039"/>
                    <measurement group_id="O6" value="0.100" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values of Forced Expiratory Volume (FEV1) at Each Timepoint</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
        <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h</time_frame>
        <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values of Forced Expiratory Volume (FEV1) at Each Timepoint</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
          <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.25 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.696" spread="0.030"/>
                    <measurement group_id="O2" value="2.863" spread="0.030"/>
                    <measurement group_id="O3" value="2.886" spread="0.030"/>
                    <measurement group_id="O4" value="2.934" spread="0.030"/>
                    <measurement group_id="O5" value="3.007" spread="0.030"/>
                    <measurement group_id="O6" value="3.106" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.719" spread="0.037"/>
                    <measurement group_id="O2" value="3.000" spread="0.037"/>
                    <measurement group_id="O3" value="3.025" spread="0.037"/>
                    <measurement group_id="O4" value="3.098" spread="0.037"/>
                    <measurement group_id="O5" value="3.133" spread="0.037"/>
                    <measurement group_id="O6" value="3.147" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.746" spread="0.039"/>
                    <measurement group_id="O2" value="3.034" spread="0.038"/>
                    <measurement group_id="O3" value="3.081" spread="0.038"/>
                    <measurement group_id="O4" value="3.136" spread="0.038"/>
                    <measurement group_id="O5" value="3.188" spread="0.039"/>
                    <measurement group_id="O6" value="3.123" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.771" spread="0.041"/>
                    <measurement group_id="O2" value="3.069" spread="0.041"/>
                    <measurement group_id="O3" value="3.102" spread="0.041"/>
                    <measurement group_id="O4" value="3.190" spread="0.041"/>
                    <measurement group_id="O5" value="3.196" spread="0.041"/>
                    <measurement group_id="O6" value="3.040" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.774" spread="0.044"/>
                    <measurement group_id="O2" value="3.058" spread="0.044"/>
                    <measurement group_id="O3" value="3.124" spread="0.044"/>
                    <measurement group_id="O4" value="3.167" spread="0.044"/>
                    <measurement group_id="O5" value="3.211" spread="0.044"/>
                    <measurement group_id="O6" value="2.937" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.722" spread="0.038"/>
                    <measurement group_id="O2" value="3.008" spread="0.038"/>
                    <measurement group_id="O3" value="3.087" spread="0.038"/>
                    <measurement group_id="O4" value="3.157" spread="0.038"/>
                    <measurement group_id="O5" value="3.194" spread="0.038"/>
                    <measurement group_id="O6" value="2.812" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.715" spread="0.040"/>
                    <measurement group_id="O2" value="3.033" spread="0.039"/>
                    <measurement group_id="O3" value="3.062" spread="0.039"/>
                    <measurement group_id="O4" value="3.139" spread="0.039"/>
                    <measurement group_id="O5" value="3.180" spread="0.039"/>
                    <measurement group_id="O6" value="2.772" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.659" spread="0.044"/>
                    <measurement group_id="O2" value="2.943" spread="0.043"/>
                    <measurement group_id="O3" value="2.980" spread="0.043"/>
                    <measurement group_id="O4" value="3.035" spread="0.043"/>
                    <measurement group_id="O5" value="3.111" spread="0.043"/>
                    <measurement group_id="O6" value="2.669" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="59"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.597" spread="0.042"/>
                    <measurement group_id="O2" value="2.903" spread="0.041"/>
                    <measurement group_id="O3" value="2.941" spread="0.041"/>
                    <measurement group_id="O4" value="3.018" spread="0.041"/>
                    <measurement group_id="O5" value="3.094" spread="0.042"/>
                    <measurement group_id="O6" value="2.683" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.588" spread="0.040"/>
                    <measurement group_id="O2" value="2.804" spread="0.039"/>
                    <measurement group_id="O3" value="2.836" spread="0.040"/>
                    <measurement group_id="O4" value="2.923" spread="0.040"/>
                    <measurement group_id="O5" value="2.985" spread="0.040"/>
                    <measurement group_id="O6" value="2.562" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.618" spread="0.040"/>
                    <measurement group_id="O2" value="2.840" spread="0.039"/>
                    <measurement group_id="O3" value="2.890" spread="0.040"/>
                    <measurement group_id="O4" value="2.948" spread="0.040"/>
                    <measurement group_id="O5" value="3.019" spread="0.040"/>
                    <measurement group_id="O6" value="2.605" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.689" spread="0.042"/>
                    <measurement group_id="O2" value="2.823" spread="0.041"/>
                    <measurement group_id="O3" value="2.798" spread="0.041"/>
                    <measurement group_id="O4" value="2.892" spread="0.041"/>
                    <measurement group_id="O5" value="2.929" spread="0.041"/>
                    <measurement group_id="O6" value="2.690" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.723" spread="0.034"/>
                    <measurement group_id="O2" value="2.956" spread="0.033"/>
                    <measurement group_id="O3" value="2.972" spread="0.033"/>
                    <measurement group_id="O4" value="3.033" spread="0.033"/>
                    <measurement group_id="O5" value="3.089" spread="0.033"/>
                    <measurement group_id="O6" value="3.142" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.</description>
        <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h</time_frame>
        <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.</description>
          <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.25 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.048" spread="0.030"/>
                    <measurement group_id="O2" value="0.214" spread="0.030"/>
                    <measurement group_id="O3" value="0.237" spread="0.030"/>
                    <measurement group_id="O4" value="0.285" spread="0.030"/>
                    <measurement group_id="O5" value="0.358" spread="0.030"/>
                    <measurement group_id="O6" value="0.457" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.071" spread="0.034"/>
                    <measurement group_id="O2" value="0.304" spread="0.033"/>
                    <measurement group_id="O3" value="0.319" spread="0.033"/>
                    <measurement group_id="O4" value="0.381" spread="0.033"/>
                    <measurement group_id="O5" value="0.437" spread="0.033"/>
                    <measurement group_id="O6" value="0.490" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.067" spread="0.037"/>
                    <measurement group_id="O2" value="0.348" spread="0.037"/>
                    <measurement group_id="O3" value="0.373" spread="0.037"/>
                    <measurement group_id="O4" value="0.446" spread="0.037"/>
                    <measurement group_id="O5" value="0.481" spread="0.037"/>
                    <measurement group_id="O6" value="0.495" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.094" spread="0.039"/>
                    <measurement group_id="O2" value="0.382" spread="0.038"/>
                    <measurement group_id="O3" value="0.429" spread="0.038"/>
                    <measurement group_id="O4" value="0.484" spread="0.038"/>
                    <measurement group_id="O5" value="0.536" spread="0.039"/>
                    <measurement group_id="O6" value="0.471" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.119" spread="0.041"/>
                    <measurement group_id="O2" value="0.416" spread="0.041"/>
                    <measurement group_id="O3" value="0.450" spread="0.041"/>
                    <measurement group_id="O4" value="0.537" spread="0.041"/>
                    <measurement group_id="O5" value="0.543" spread="0.041"/>
                    <measurement group_id="O6" value="0.388" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.121" spread="0.044"/>
                    <measurement group_id="O2" value="0.406" spread="0.044"/>
                    <measurement group_id="O3" value="0.471" spread="0.044"/>
                    <measurement group_id="O4" value="0.515" spread="0.044"/>
                    <measurement group_id="O5" value="0.558" spread="0.044"/>
                    <measurement group_id="O6" value="0.284" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.067" spread="0.038"/>
                    <measurement group_id="O2" value="0.353" spread="0.038"/>
                    <measurement group_id="O3" value="0.432" spread="0.038"/>
                    <measurement group_id="O4" value="0.501" spread="0.038"/>
                    <measurement group_id="O5" value="0.539" spread="0.038"/>
                    <measurement group_id="O6" value="0.157" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.056" spread="0.040"/>
                    <measurement group_id="O2" value="0.374" spread="0.039"/>
                    <measurement group_id="O3" value="0.403" spread="0.039"/>
                    <measurement group_id="O4" value="0.480" spread="0.039"/>
                    <measurement group_id="O5" value="0.521" spread="0.039"/>
                    <measurement group_id="O6" value="0.113" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="0.044"/>
                    <measurement group_id="O2" value="0.288" spread="0.043"/>
                    <measurement group_id="O3" value="0.326" spread="0.043"/>
                    <measurement group_id="O4" value="0.380" spread="0.043"/>
                    <measurement group_id="O5" value="0.456" spread="0.043"/>
                    <measurement group_id="O6" value="0.014" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="59"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.053" spread="0.042"/>
                    <measurement group_id="O2" value="0.253" spread="0.041"/>
                    <measurement group_id="O3" value="0.291" spread="0.041"/>
                    <measurement group_id="O4" value="0.367" spread="0.041"/>
                    <measurement group_id="O5" value="0.443" spread="0.042"/>
                    <measurement group_id="O6" value="0.032" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.067" spread="0.040"/>
                    <measurement group_id="O2" value="0.148" spread="0.039"/>
                    <measurement group_id="O3" value="0.181" spread="0.040"/>
                    <measurement group_id="O4" value="0.268" spread="0.040"/>
                    <measurement group_id="O5" value="0.330" spread="0.040"/>
                    <measurement group_id="O6" value="-0.093" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.040" spread="0.040"/>
                    <measurement group_id="O2" value="0.183" spread="0.039"/>
                    <measurement group_id="O3" value="0.233" spread="0.040"/>
                    <measurement group_id="O4" value="0.291" spread="0.040"/>
                    <measurement group_id="O5" value="0.362" spread="0.040"/>
                    <measurement group_id="O6" value="-0.052" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" spread="0.042"/>
                    <measurement group_id="O2" value="0.169" spread="0.041"/>
                    <measurement group_id="O3" value="0.144" spread="0.041"/>
                    <measurement group_id="O4" value="0.238" spread="0.041"/>
                    <measurement group_id="O5" value="0.275" spread="0.041"/>
                    <measurement group_id="O6" value="0.036" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.</description>
        <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h</time_frame>
        <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.</description>
          <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.25 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.519" spread="1.090"/>
                    <measurement group_id="O2" value="8.325" spread="1.084"/>
                    <measurement group_id="O3" value="8.846" spread="1.084"/>
                    <measurement group_id="O4" value="10.789" spread="1.084"/>
                    <measurement group_id="O5" value="13.511" spread="1.081"/>
                    <measurement group_id="O6" value="17.744" spread="1.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.449" spread="1.205"/>
                    <measurement group_id="O2" value="11.757" spread="1.199"/>
                    <measurement group_id="O3" value="12.006" spread="1.199"/>
                    <measurement group_id="O4" value="14.362" spread="1.199"/>
                    <measurement group_id="O5" value="16.715" spread="1.196"/>
                    <measurement group_id="O6" value="18.806" spread="12.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.407" spread="1.356"/>
                    <measurement group_id="O2" value="13.452" spread="1.350"/>
                    <measurement group_id="O3" value="14.307" spread="1.350"/>
                    <measurement group_id="O4" value="16.927" spread="1.350"/>
                    <measurement group_id="O5" value="18.336" spread="1.352"/>
                    <measurement group_id="O6" value="19.085" spread="1.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.520" spread="1.434"/>
                    <measurement group_id="O2" value="14.741" spread="1.427"/>
                    <measurement group_id="O3" value="16.371" spread="1.428"/>
                    <measurement group_id="O4" value="18.509" spread="1.428"/>
                    <measurement group_id="O5" value="20.226" spread="1.430"/>
                    <measurement group_id="O6" value="17.755" spread="1.438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.435" spread="1.479"/>
                    <measurement group_id="O2" value="15.965" spread="1.472"/>
                    <measurement group_id="O3" value="17.190" spread="1.472"/>
                    <measurement group_id="O4" value="20.357" spread="1.477"/>
                    <measurement group_id="O5" value="20.550" spread="1.470"/>
                    <measurement group_id="O6" value="14.537" spread="1.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.288" spread="1.596"/>
                    <measurement group_id="O2" value="15.400" spread="1.589"/>
                    <measurement group_id="O3" value="17.960" spread="1.590"/>
                    <measurement group_id="O4" value="19.454" spread="1.590"/>
                    <measurement group_id="O5" value="21.155" spread="1.587"/>
                    <measurement group_id="O6" value="10.608" spread="1.600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.682" spread="1.439"/>
                    <measurement group_id="O2" value="13.661" spread="1.424"/>
                    <measurement group_id="O3" value="16.490" spread="1.425"/>
                    <measurement group_id="O4" value="19.080" spread="1.425"/>
                    <measurement group_id="O5" value="20.612" spread="1.421"/>
                    <measurement group_id="O6" value="5.796" spread="1.438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.752" spread="1.505"/>
                    <measurement group_id="O2" value="14.118" spread="1.482"/>
                    <measurement group_id="O3" value="15.128" spread="1.482"/>
                    <measurement group_id="O4" value="18.199" spread="1.482"/>
                    <measurement group_id="O5" value="19.733" spread="1.478"/>
                    <measurement group_id="O6" value="4.493" spread="1.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.402" spread="1.627"/>
                    <measurement group_id="O2" value="10.847" spread="1.614"/>
                    <measurement group_id="O3" value="12.388" spread="1.614"/>
                    <measurement group_id="O4" value="14.251" spread="1.614"/>
                    <measurement group_id="O5" value="17.170" spread="1.616"/>
                    <measurement group_id="O6" value="0.997" spread="1.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="59"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.903" spread="1.559"/>
                    <measurement group_id="O2" value="9.427" spread="1.551"/>
                    <measurement group_id="O3" value="11.008" spread="1.544"/>
                    <measurement group_id="O4" value="11.771" spread="1.544"/>
                    <measurement group_id="O5" value="16.716" spread="1.555"/>
                    <measurement group_id="O6" value="1.892" spread="1.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.117" spread="1.464"/>
                    <measurement group_id="O2" value="5.451" spread="1.444"/>
                    <measurement group_id="O3" value="6.955" spread="1.445"/>
                    <measurement group_id="O4" value="9.893" spread="1.445"/>
                    <measurement group_id="O5" value="12.375" spread="1.449"/>
                    <measurement group_id="O6" value="-3.649" spread="1.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.611" spread="1.473"/>
                    <measurement group_id="O2" value="7.084" spread="1.453"/>
                    <measurement group_id="O3" value="8.918" spread="1.461"/>
                    <measurement group_id="O4" value="10.975" spread="1.461"/>
                    <measurement group_id="O5" value="13.716" spread="1.458"/>
                    <measurement group_id="O6" value="-1.736" spread="1.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.904" spread="1.574"/>
                    <measurement group_id="O2" value="6.396" spread="1.554"/>
                    <measurement group_id="O3" value="5.589" spread="1.555"/>
                    <measurement group_id="O4" value="8.742" spread="1.555"/>
                    <measurement group_id="O5" value="10.370" spread="1.558"/>
                    <measurement group_id="O6" value="2.098" spread="1.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Peak Forced Vital Capacity (FVC)</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
        <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Peak Forced Vital Capacity (FVC)</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.222" spread="0.034"/>
                    <measurement group_id="O2" value="0.317" spread="0.034"/>
                    <measurement group_id="O3" value="0.329" spread="0.034"/>
                    <measurement group_id="O4" value="0.361" spread="0.034"/>
                    <measurement group_id="O5" value="0.380" spread="0.034"/>
                    <measurement group_id="O6" value="0.361" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Forced Vital Capacity (FVC)</title>
        <description>The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
        <time_frame>+15 min, +30 min, +1 h, +2 h, +3 h, +4 h</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Forced Vital Capacity (FVC)</title>
          <description>The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.483" spread="0.034"/>
                    <measurement group_id="O2" value="4.578" spread="0.034"/>
                    <measurement group_id="O3" value="4.590" spread="0.034"/>
                    <measurement group_id="O4" value="4.622" spread="0.034"/>
                    <measurement group_id="O5" value="4.641" spread="0.034"/>
                    <measurement group_id="O6" value="4.622" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Forced Vital Capacity (FVC)</title>
        <description>The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
        <time_frame>+15 min, +30 min, +1 h, +2 h, +3 h, +4 h</time_frame>
        <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Forced Vital Capacity (FVC)</title>
          <description>The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
          <population>ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.4"/>
                    <measurement group_id="O2" value="1.8" spread="1.4"/>
                    <measurement group_id="O3" value="2.3" spread="1.4"/>
                    <measurement group_id="O4" value="2.1" spread="1.2"/>
                    <measurement group_id="O5" value="2.2" spread="1.4"/>
                    <measurement group_id="O6" value="1.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Trough Forced Vital Capacity (FVC)</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
        <time_frame>Baseline and +23 h +24 h post-dose</time_frame>
        <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Trough Forced Vital Capacity (FVC)</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
          <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="60"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.028" spread="0.035"/>
                    <measurement group_id="O2" value="0.094" spread="0.035"/>
                    <measurement group_id="O3" value="0.050" spread="0.035"/>
                    <measurement group_id="O4" value="0.111" spread="0.035"/>
                    <measurement group_id="O5" value="0.120" spread="0.035"/>
                    <measurement group_id="O6" value="-0.065" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Normalized Forced Vital Capacity (FVC) Area Under the Curve (AUC)</title>
        <description>FVC was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
        <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h and +24 h</time_frame>
        <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Normalized Forced Vital Capacity (FVC) Area Under the Curve (AUC)</title>
          <description>FVC was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.</description>
          <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="59"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.017" spread="0.031"/>
                    <measurement group_id="O2" value="0.135" spread="0.031"/>
                    <measurement group_id="O3" value="0.109" spread="0.030"/>
                    <measurement group_id="O4" value="0.169" spread="0.030"/>
                    <measurement group_id="O5" value="0.192" spread="0.031"/>
                    <measurement group_id="O6" value="0.054" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values of Forced Vital Capacity (FVC) at Each Timepoint</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.</description>
        <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h</time_frame>
        <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values of Forced Vital Capacity (FVC) at Each Timepoint</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.</description>
          <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.25h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.295" spread="0.030"/>
                    <measurement group_id="O2" value="4.420" spread="0.030"/>
                    <measurement group_id="O3" value="4.368" spread="0.030"/>
                    <measurement group_id="O4" value="4.383" spread="0.030"/>
                    <measurement group_id="O5" value="4.417" spread="0.030"/>
                    <measurement group_id="O6" value="4.471" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.320" spread="0.032"/>
                    <measurement group_id="O2" value="4.458" spread="0.032"/>
                    <measurement group_id="O3" value="4.405" spread="0.032"/>
                    <measurement group_id="O4" value="4.438" spread="0.032"/>
                    <measurement group_id="O5" value="4.443" spread="0.032"/>
                    <measurement group_id="O6" value="4.502" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.295" spread="0.034"/>
                    <measurement group_id="O2" value="4.442" spread="0.034"/>
                    <measurement group_id="O3" value="4.429" spread="0.034"/>
                    <measurement group_id="O4" value="4.480" spread="0.034"/>
                    <measurement group_id="O5" value="4.498" spread="0.034"/>
                    <measurement group_id="O6" value="4.502" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.321" spread="0.034"/>
                    <measurement group_id="O2" value="4.445" spread="0.034"/>
                    <measurement group_id="O3" value="4.444" spread="0.034"/>
                    <measurement group_id="O4" value="4.495" spread="0.034"/>
                    <measurement group_id="O5" value="4.512" spread="0.034"/>
                    <measurement group_id="O6" value="4.477" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.352" spread="0.036"/>
                    <measurement group_id="O2" value="4.462" spread="0.035"/>
                    <measurement group_id="O3" value="4.472" spread="0.035"/>
                    <measurement group_id="O4" value="4.505" spread="0.035"/>
                    <measurement group_id="O5" value="4.505" spread="0.035"/>
                    <measurement group_id="O6" value="4.454" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.316" spread="0.035"/>
                    <measurement group_id="O2" value="4.459" spread="0.035"/>
                    <measurement group_id="O3" value="4.462" spread="0.035"/>
                    <measurement group_id="O4" value="4.463" spread="0.035"/>
                    <measurement group_id="O5" value="4.517" spread="0.034"/>
                    <measurement group_id="O6" value="4.398" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.322" spread="0.033"/>
                    <measurement group_id="O2" value="4.413" spread="0.033"/>
                    <measurement group_id="O3" value="1.411" spread="0.033"/>
                    <measurement group_id="O4" value="4.464" spread="0.033"/>
                    <measurement group_id="O5" value="4.513" spread="0.033"/>
                    <measurement group_id="O6" value="4.360" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.325" spread="0.035"/>
                    <measurement group_id="O2" value="4.456" spread="0.035"/>
                    <measurement group_id="O3" value="4.412" spread="0.035"/>
                    <measurement group_id="O4" value="4.487" spread="0.035"/>
                    <measurement group_id="O5" value="4.499" spread="0.035"/>
                    <measurement group_id="O6" value="4.335" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.310" spread="0.036"/>
                    <measurement group_id="O2" value="4.409" spread="0.036"/>
                    <measurement group_id="O3" value="4.349" spread="0.036"/>
                    <measurement group_id="O4" value="4.414" spread="0.036"/>
                    <measurement group_id="O5" value="4.453" spread="0.036"/>
                    <measurement group_id="O6" value="4.277" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="59"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.235" spread="0.036"/>
                    <measurement group_id="O2" value="4.357" spread="0.036"/>
                    <measurement group_id="O3" value="4.360" spread="0.036"/>
                    <measurement group_id="O4" value="4.436" spread="0.036"/>
                    <measurement group_id="O5" value="4.458" spread="0.036"/>
                    <measurement group_id="O6" value="4.269" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.244" spread="0.037"/>
                    <measurement group_id="O2" value="4.366" spread="0.036"/>
                    <measurement group_id="O3" value="4.303" spread="0.036"/>
                    <measurement group_id="O4" value="4.375" spread="0.036"/>
                    <measurement group_id="O5" value="4.367" spread="0.036"/>
                    <measurement group_id="O6" value="4.223" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.238" spread="0.038"/>
                    <measurement group_id="O2" value="4.359" spread="0.037"/>
                    <measurement group_id="O3" value="4.335" spread="0.038"/>
                    <measurement group_id="O4" value="4.384" spread="0.038"/>
                    <measurement group_id="O5" value="4.410" spread="0.038"/>
                    <measurement group_id="O6" value="4.193" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.252" spread="0.040"/>
                    <measurement group_id="O2" value="4.390" spread="0.039"/>
                    <measurement group_id="O3" value="4.280" spread="0.039"/>
                    <measurement group_id="O4" value="4.352" spread="0.039"/>
                    <measurement group_id="O5" value="4.381" spread="0.039"/>
                    <measurement group_id="O6" value="4.284" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Vital Capacity (FVC) at Each Timepoint</title>
        <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.</description>
        <time_frame>Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h</time_frame>
        <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
          <group group_id="O2">
            <title>LAS100977 0.313 μg</title>
            <description>Dry powder administered via the Genuair® inhaler</description>
          </group>
          <group group_id="O3">
            <title>LAS100977 0.625 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O4">
            <title>LAS100977 1.25 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O5">
            <title>LAS100977 2.5 μg</title>
            <description>Dry powder for inhalation administered via Genuair®</description>
          </group>
          <group group_id="O6">
            <title>Salbutamol 400 μg</title>
            <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Vital Capacity (FVC) at Each Timepoint</title>
          <description>Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.</description>
          <population>Patients in the ITT population with available data at the timepoints of interest. ITT population defined as patients who took at least one dose of investigational medicinal product and had at least a baseline and one post-dose value of FEV1 from at least one treatment period</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.25 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038" spread="0.030"/>
                    <measurement group_id="O2" value="0.162" spread="0.030"/>
                    <measurement group_id="O3" value="0.111" spread="0.030"/>
                    <measurement group_id="O4" value="0.125" spread="0.030"/>
                    <measurement group_id="O5" value="0.159" spread="0.030"/>
                    <measurement group_id="O6" value="0.213" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.059" spread="0.032"/>
                    <measurement group_id="O2" value="0.197" spread="0.032"/>
                    <measurement group_id="O3" value="0.144" spread="0.032"/>
                    <measurement group_id="O4" value="0.177" spread="0.032"/>
                    <measurement group_id="O5" value="0.182" spread="0.032"/>
                    <measurement group_id="O6" value="0.241" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" spread="0.034"/>
                    <measurement group_id="O2" value="0.182" spread="0.034"/>
                    <measurement group_id="O3" value="0.169" spread="0.034"/>
                    <measurement group_id="O4" value="0.219" spread="0.034"/>
                    <measurement group_id="O5" value="0.237" spread="0.034"/>
                    <measurement group_id="O6" value="0.242" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.060" spread="0.034"/>
                    <measurement group_id="O2" value="0.184" spread="0.034"/>
                    <measurement group_id="O3" value="0.183" spread="0.034"/>
                    <measurement group_id="O4" value="0.234" spread="0.034"/>
                    <measurement group_id="O5" value="0.252" spread="0.034"/>
                    <measurement group_id="O6" value="0.217" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.089" spread="0.036"/>
                    <measurement group_id="O2" value="0.199" spread="0.035"/>
                    <measurement group_id="O3" value="0.209" spread="0.035"/>
                    <measurement group_id="O4" value="0.241" spread="0.035"/>
                    <measurement group_id="O5" value="0.242" spread="0.035"/>
                    <measurement group_id="O6" value="0.191" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" spread="0.035"/>
                    <measurement group_id="O2" value="0.198" spread="0.035"/>
                    <measurement group_id="O3" value="0.201" spread="0.035"/>
                    <measurement group_id="O4" value="0.202" spread="0.035"/>
                    <measurement group_id="O5" value="0.256" spread="0.034"/>
                    <measurement group_id="O6" value="0.137" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.057" spread="0.033"/>
                    <measurement group_id="O2" value="0.149" spread="0.033"/>
                    <measurement group_id="O3" value="0.147" spread="0.033"/>
                    <measurement group_id="O4" value="0.200" spread="0.033"/>
                    <measurement group_id="O5" value="0.249" spread="0.033"/>
                    <measurement group_id="O6" value="0.096" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.054" spread="0.035"/>
                    <measurement group_id="O2" value="0.185" spread="0.035"/>
                    <measurement group_id="O3" value="0.141" spread="0.035"/>
                    <measurement group_id="O4" value="0.216" spread="0.035"/>
                    <measurement group_id="O5" value="0.228" spread="0.035"/>
                    <measurement group_id="O6" value="0.064" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.042" spread="0.036"/>
                    <measurement group_id="O2" value="0.141" spread="0.036"/>
                    <measurement group_id="O3" value="0.081" spread="0.036"/>
                    <measurement group_id="O4" value="0.146" spread="0.036"/>
                    <measurement group_id="O5" value="0.185" spread="0.036"/>
                    <measurement group_id="O6" value="0.001" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="59"/>
                    <count group_id="O6" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.027" spread="0.036"/>
                    <measurement group_id="O2" value="0.095" spread="0.036"/>
                    <measurement group_id="O3" value="0.097" spread="0.036"/>
                    <measurement group_id="O4" value="0.173" spread="0.036"/>
                    <measurement group_id="O5" value="0.195" spread="0.036"/>
                    <measurement group_id="O6" value="0.006" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.022" spread="0.037"/>
                    <measurement group_id="O2" value="0.101" spread="0.036"/>
                    <measurement group_id="O3" value="0.038" spread="0.036"/>
                    <measurement group_id="O4" value="0.110" spread="0.036"/>
                    <measurement group_id="O5" value="0.102" spread="0.036"/>
                    <measurement group_id="O6" value="-0.043" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.034" spread="0.038"/>
                    <measurement group_id="O2" value="0.086" spread="0.037"/>
                    <measurement group_id="O3" value="0.063" spread="0.038"/>
                    <measurement group_id="O4" value="0.111" spread="0.038"/>
                    <measurement group_id="O5" value="0.137" spread="0.038"/>
                    <measurement group_id="O6" value="-0.079" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hr</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="60"/>
                    <count group_id="O6" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="0.040"/>
                    <measurement group_id="O2" value="0.128" spread="0.039"/>
                    <measurement group_id="O3" value="0.018" spread="0.039"/>
                    <measurement group_id="O4" value="0.089" spread="0.039"/>
                    <measurement group_id="O5" value="0.118" spread="0.039"/>
                    <measurement group_id="O6" value="0.022" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 (±2) days after last intake of investigational medicinal product</time_frame>
      <desc>Safety population defined as all randomized patients who took at least 1 dose of investigational medicinal product The total number of patients in the safety population was 62; due to study drop-out and the crossover study design, not all patients received all treatments</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Dry powder administered via the Genuair® inhaler or pressurised inhalation suspension administered via Ventolin Evohaler®</description>
        </group>
        <group group_id="E2">
          <title>LAS100977 0.313 μg</title>
          <description>Dry powder administered via the Genuair® inhaler</description>
        </group>
        <group group_id="E3">
          <title>LAS100977 0.625 μg</title>
          <description>Dry powder for inhalation administered via Genuair®</description>
        </group>
        <group group_id="E4">
          <title>LAS100977 1.25 μg</title>
          <description>Dry powder for inhalation administered via Genuair®</description>
        </group>
        <group group_id="E5">
          <title>LAS100977 2.5 μg</title>
          <description>Dry powder for inhalation administered via Genuair®</description>
        </group>
        <group group_id="E6">
          <title>Salbutamol 400 μg</title>
          <description>Pressurised inhalation suspension administered via Ventolin Evohaler®</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication and/or presentation whether complete or partial, of any part of the data or results of this trial will be subject to revision and written agreement between the investigator and sponsor</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

